The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.
A key distinction for oncologists is that PIK3CA mutations are typically "truncal" (present from baseline), whereas ESR1 mutations are "acquired" after exposure to aromatase inhibitors. This biological difference dictates when and how to test for each biomarker throughout a patient's treatment journey.
Even with contemporaneously collected samples, biomarker concordance between solid tissue and liquid biopsies is not uniform. Data shows ESR1 mutations are consistently more likely to be discordant—often found only in liquid—than PIK3CA or AKT mutations, reinforcing the need for gene-specific testing strategies.
Clinicians must recognize that liquid and solid biopsies show significant discordance. ESR1 mutations are more frequently detected in liquid assays, while PIK3CA mutations are more often found in solid tissue. This variability by gene directly impacts the optimal testing strategy for patients.
Next-generation mutant-specific PI3K inhibitors could lead to complex biomarker requirements. A future drug label might require a PIK3CA mutation for eligibility but simultaneously exclude patients who also have downstream PTEN or AKT alterations, which can confer resistance.
The rapid evolution of clinical evidence is reflected in ASCO guidelines. In just one year (2022 to 2023), recommendations for ESR1 testing in HR+ metastatic breast cancer changed from having insufficient data to recommending routine testing upon progression, highlighting the pace of change in oncology.
The novel DiviTum TKA assay measures cell proliferation in real-time. Patterns of TKA level suppression, rebound, or lack of suppression within the first month of CDK4/6 inhibitor therapy strongly predict a patient's long-term progression-free survival, offering an early look at treatment efficacy.